<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="0" ids="33838">Nucleoside</z:chebi> analogs (NAs) are considered as appropriate agents in the treatment of <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenstr√∂m macroglobulinemia</z:e> (WM), a lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003745'>Sporadic</z:hpo> reports on increased incidence of transformation to high-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and development of therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>/<z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) among patients with WM treated with NAs prompted us to examine the incidence of such events in a large population of patients with WM </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We examined the incidence of these events in 439 patients with WM, 193 and 136 of whom were previously treated with and without an NA, respectively, and 110 of whom had similar long-term follow-up without treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The median follow-up for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 5 years </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Overall, 12 patients (6.2%) either developed transformation (n = 9; 4.7%) or developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 3; 1.6%) among NA-treated patients, compared with one patient (0.4%) who developed transformation in the non-NA treated group (P &lt; .001); no such events occurred among untreated patients </plain></SENT>
<SENT sid="5" pm="."><plain>Transformation and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> occurred at a median of 5 years from <z:hpo ids='HP_0003674'>onset</z:hpo> of NA therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The median survival of NA-treated patients who developed transformation did not differ from other NA-treated patients as a result of effective salvage treatment used for transformed disease </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:hpo ids='HP_0000001'>all</z:hpo> NA-treated patients who developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> died at a median of 5 months </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: These data demonstrate an increased incidence of disease transformation to high-grade NHL and the development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> among patients with WM treated with NAs </plain></SENT>
</text></document>